This Article Full Text Full Text (PDF) All Versions of this Article: 38/2/441    most recent 01.STR.0000254602.58896.d2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robinson, J. G. Articles by Wallace, R. Search for Related Content PubMed PubMed Citation Articles by Robinson, J. G. Articles by Wallace, R. Related Collections Cerebrovascular disease/stroke Other hypertension Lipids Primary prevention Related Article

(Stroke. 2007;38:441.)
© 2007 American Heart Association, Inc.

Progress Reviews

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?

Jennifer G. Robinson, MD, MPH; George Bakris, MD; James Torner, PhD; Neil J. Stone, MD Robert Wallace, MD

From the University of Iowa, Iowa City (J.G.R., J.T., R.W.); University of Chicago, Chicago, Ill (G.B.); and Northwestern University, Evanston, Ill (N.J.S.).

Correspondence to Jennifer G. Robinson, MD, MPH, Lipid Research Clinic, Departments of Epidemiology and Medicine, University of Iowa, 200 Hawkins Dr SE, 226 GH, Iowa City, IA 52242. E-mail jennifer-g-robinson{at}uiowa.edu

Background and Purpose— Statins have been shown conclusively to reduce the risk of cardiovascular events in subjects with clinical cardiovascular disease or diabetes aged 65 to 80 years of age. However, few data are available for primary prevention of cardiovascular disease in those aged 70 years.

Summary of Review— A moderate-dose statin was of little benefit in a population aged 70 to 82 years when given for 3 years in the setting of suboptimally treated blood pressure. More evidence supports the use of blood pressure–lowering medications, but few data are available regarding the appropriate blood pressure target and most effective agents in the elderly. Some evidence also suggests that the elderly could experience higher mortality with antihypertensive treatment. These findings, along with greater safety concerns and an increasing number of competing risks and medical conditions with advancing age, make it imperative to carefully evaluate the risk/benefit balance from treating hypercholesterolemia and hypertension in persons aged 70 years.

Conclusions— We propose a 5-year 2x2 factorial trial of primary prevention in the elderly that will (1) evaluate whether statin therapy will reduce the risk of cardiovascular events when added to the treatment of hypertension to achieve a blood pressure <140/90 mm Hg in most patients and (2) determine the most appropriate blood pressure regimen for the prevention of cardiovascular and renal events.

Key Words: cardiovascular disease • elderly • hypertension • primary prevention • statins

Related Article:

Uncertainty of Management of Blood Pressure and Lipids in the Elderly: Time for a Primary Prevention Trial

Philip B. Gorelick
Stroke 2007 38: 212-213. [Full Text] [PDF]

This article has been cited by other articles:

				S. Hallan, B. Astor, S. Romundstad, K. Aasarod, K. Kvenild, and J. Coresh Association of Kidney Function and Albuminuria With Cardiovascular Mortality in Older vs Younger Individuals: The HUNT II Study Arch Intern Med, December 10, 2007; 167(22): 2490 - 2496. [Abstract] [Full Text] [PDF]

				P. B. Gorelick Uncertainty of Management of Blood Pressure and Lipids in the Elderly: Time for a Primary Prevention Trial Stroke, February 1, 2007; 38(2): 212 - 213. [Full Text] [PDF]